Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.42 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27738953 | 1.00 | PTGS2 (0.43) | PTGS2NFE2L2GPR27ARSMN1; SMN2 | |
| SCHEMBL27717781 | 0.93 | CYP1A2 (0.46) | PTGS2NFE2L2SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL5417301 | 0.93 | CYP1A2 (0.46) | PTGS2NFE2L2SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL4618986 | 0.88 | PPARG (0.47) | ARSMN1; SMN2RAB9AMEN1NPC1 | |
| SCHEMBL4255430 | 0.86 | NFE2L2 (0.52) | PTGS2NFE2L2SMN1; SMN2RAB9ACYP1A2 | |
| SCHEMBL27726710 | 0.86 | NFE2L2 (0.52) | PTGS2NFE2L2SMN1; SMN2RAB9ACYP1A2 | |
| SCHEMBL27739103 | 0.85 | NFE2L2 (0.41) | NFE2L2GPR27SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL27738934 | 0.85 | PTGES2 (0.49) | PTGS2NFE2L2SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL5420996 | 0.85 | NFE2L2 (0.41) | NFE2L2GPR27SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL5417526 | 0.85 | PTGES2 (0.49) | PTGS2NFE2L2SMN1; SMN2RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101268042-A | Styryl sulfonamides, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | CN | claimed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | claimed |
| CN-101268042-A | Styryl sulfonamides, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | CN | disclosed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270874-A1 | Styrylsulfonamides | STS, SULT1E1, BRCA1 | PTGS2 3624/4885NFE2L2 1842/4885GPR27 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.